サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1566751

腫瘍・がん治療薬市場：薬剤クラス別、適応症別：世界の機会分析と産業予測、2024-2033年

Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy , Hormonal Therapy), By Indication : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日: | 発行: Allied Market Research | ページ情報: 英文 250 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.54円
腫瘍・がん治療薬市場：薬剤クラス別、適応症別：世界の機会分析と産業予測、2024-2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 250 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の腫瘍・がん治療薬市場は、2023年に1,670億米ドルと評価され、2024～2033年にかけてCAGR 7.2%で成長し、2033年には3,352億米ドルに達すると予測されています。

腫瘍・がん治療薬には、さまざまな種類のがんの診断、治療薬、管理に特化した医薬品が含まれます。これらの医薬品は、がん細胞を標的としたり、がんの増殖や転移に関与するプロセスを阻害したりします。伝統的な化学療法から免疫療法や精密医療のような標的療法まで、幅広い治療薬アプローチが含まれます。

世界の腫瘍・がん治療薬市場は、高齢化、ライフスタイルの変化、環境暴露別の世界のがん罹患率の上昇が、革新的な治療薬法の需要を牽引しています。このような患者数の増加は、多様ながん種やアンメット・メディカル・ニーズに対応するための継続的な研究開発努力の必要性を浮き彫りにしています。さらに、科学技術のセグメント、特に分子生物学、ゲノム科学、免疫療法などのセグメントの進歩が、抗がん剤開発の大幅な進歩を後押ししています。がんの進行を促進する特定の分子異常に焦点を当てる精密医療戦略の台頭は、ますます顕著になってきています。その結果、より強力で害の少ない治療薬法が生み出され、腫瘍・がん治療薬市場の成長に拍車をかけています。

しかし、腫瘍・がん治療薬の開発には多額の費用がかかり、前臨床試験、臨床試験、規制当局の承認に多額の投資を必要とすることが多いため、腫瘍・がん治療薬の採用は限られています。とはいえ、新しい治療薬法や薬剤に関連する規制当局からの承認は、市場参入企業にいくつかの機会をもたらすと期待されています。例えば、2023年10月、米国食品医薬品局（FDA）は夏に様々ながんに対するいくつかの新しい治療薬法を承認しました。7月、FDAはJemperli（dostarlimab）の子宮内膜がんにおける新たな適応症を承認しました。

セグメンテーション概要

腫瘍・がん治療薬市場は、薬剤クラス別、適応症別、地域別に区分されます。薬剤クラス別では、化学療法、標的療法、免疫療法（生物製剤）、ホルモン療法に分類されます。適応症別では、肺がん、胃がん、大腸がん、乳がん、前立腺がん、肝臓がん、食道がん、子宮頸がん、腎臓がん、膀胱がん、その他のがんに分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析しています。

主要調査結果

薬剤クラス別では、標的療法セグメントが2023年に最大の市場シェアを占めました。

適応症別では、乳がんセグメントが2023年の市場で最も高いシェアを占めました。

地域別では、北米が2023年の腫瘍・がん治療薬市場を独占しました。

競合シナリオ

本レポートはカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細（所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式）

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 腫瘍・がん治療薬市場：薬剤クラス別

  • 市場概要
  • 化学療法
  • 標的療法
  • 免疫療法（生物学的療法）
  • ホルモン療法

第5章 腫瘍・がん治療薬市場：適応症別

  • 市場概要
  • 肺がん
  • 胃がん
  • 大腸がん
  • 乳がん
  • 前立腺がん
  • 肝臓がん
  • 食道がん
  • 子宮頸がん
  • 腎臓がん
  • 膀胱がん
  • その他のがん

第6章 腫瘍・がん治療薬市場：地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の腫瘍・がん治療薬市場
    • カナダの腫瘍・がん治療薬市場
    • メキシコの腫瘍・がん治療薬市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの腫瘍・がん治療薬市場
    • フランスの腫瘍・がん治療薬市場
    • 英国の腫瘍・がん治療薬市場
    • イタリアの腫瘍・がん治療薬市場
    • スペインの腫瘍・がん治療薬市場
    • その他の欧州の腫瘍・がん治療薬市場
  • アジア太平洋
    • 主要市場動向と機会
    • 中国の腫瘍・がん治療薬市場
    • 日本の腫瘍・がん治療薬市場
    • インドの腫瘍・がん治療薬市場
    • オーストラリア腫瘍・がん治療薬市場
    • 韓国の腫瘍・がん治療薬市場
    • その他のアジア太平洋の腫瘍・がん治療薬市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの腫瘍・がん治療薬市場
    • 南アフリカの腫瘍・がん治療薬市場
    • サウジアラビアの腫瘍・がん治療薬市場
    • その他のラテンアメリカ・中東・アフリカの腫瘍・がん治療薬市場

第7章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング（2023年）

第8章 企業プロファイル

  • AbbVie Inc.
  • Amgen
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson And Johnson
  • Merck And Co., Inc.
  • Novartis AG
  • Pfizer Inc.
目次
Product Code: A00042

The global oncology-cancer drugs market was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

The oncology/cancer drugs encompass pharmaceuticals specifically designed to diagnose, treat, and manage various types of cancer. These drugs target cancerous cells or interfere with processes involved in cancer growth and spread. It includes a wide array of therapeutic approaches, ranging from traditional chemotherapy to more targeted therapies like immunotherapy and precision medicine.

The global oncology-cancer drugs market is driven by rise in incidence of cancer globally due to aging population, lifestyle changes, and environmental exposures, which drives the demand for innovative therapies. This growing patient population highlights the need for continuous R&D efforts to address diverse cancer types and unmet medical needs. Furthermore, progress in the field of science and technology, specifically in disciplines such as molecular biology, genomics, and immunotherapy, are propelling substantial advancements in the development of cancer drugs. The rise of precision medicine strategies, which focus on specific molecular abnormalities that fuel cancer progression, is becoming increasingly prominent. This has resulted in the creation of more potent and less harmful therapies, fueling growth in the oncology drugs market.

However, high development costs of oncology drugs are extensive and costly, often requiring significant investments in preclinical studies, clinical trials, and regulatory approvals which limit the adoption of cancer drugs. Nevertheless, approval from regulatory authorities associated with new treatments and drugs is expected to create several opportunities for the market players. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved several new treatments for a range of cancers over the summer. In July, the FDA approved a new indication for Jemperli (dostarlimab) in endometrial cancer.

Segmentation Overview

The oncology-cancer drugs market is segmented into drug class type, indication, and region. Depending on drug class type, the market is categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. According to indication, it is divided into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

Depending on drug class type, the targeted therapy segment held the largest market share in 2023.

By indication, the breast cancer segment accounted for the highest share in the market in 2023.

Region wise, North America dominated the oncology-cancer drugs market in 2023.

Competitive Scenario

The major players operating in the oncology/cancer drugs market include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. Other players in oncology/cancer drugs market includes Bayer AG, Regeneron Pharmaceuticals Inc., and Eli Lilly and Company. These players have adopted several strategies, including partnerships, collaborations, and R&D to maintain their position in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophagus Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Other Cancers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • AbbVie Inc.
    • Amgen
    • Astellas Pharma Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Drug Class
  • 4.2. Chemotherapy
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Targeted Therapy
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Immunotherapy (Biologic Therapy)
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country
  • 4.5. Hormonal Therapy
    • 4.5.1. Key Market Trends, Growth Factors and Opportunities
    • 4.5.2. Market Size and Forecast, By Region
    • 4.5.3. Market Share Analysis, By Country

CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Indication
  • 5.2. Lung Cancer
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Stomach Cancer
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Colorectal Cancer
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country
  • 5.5. Breast Cancer
    • 5.5.1. Key Market Trends, Growth Factors and Opportunities
    • 5.5.2. Market Size and Forecast, By Region
    • 5.5.3. Market Share Analysis, By Country
  • 5.6. Prostate Cancer
    • 5.6.1. Key Market Trends, Growth Factors and Opportunities
    • 5.6.2. Market Size and Forecast, By Region
    • 5.6.3. Market Share Analysis, By Country
  • 5.7. Liver Cancer
    • 5.7.1. Key Market Trends, Growth Factors and Opportunities
    • 5.7.2. Market Size and Forecast, By Region
    • 5.7.3. Market Share Analysis, By Country
  • 5.8. Esophagus Cancer
    • 5.8.1. Key Market Trends, Growth Factors and Opportunities
    • 5.8.2. Market Size and Forecast, By Region
    • 5.8.3. Market Share Analysis, By Country
  • 5.9. Cervical Cancer
    • 5.9.1. Key Market Trends, Growth Factors and Opportunities
    • 5.9.2. Market Size and Forecast, By Region
    • 5.9.3. Market Share Analysis, By Country
  • 5.10. Kidney Cancer
    • 5.10.1. Key Market Trends, Growth Factors and Opportunities
    • 5.10.2. Market Size and Forecast, By Region
    • 5.10.3. Market Share Analysis, By Country
  • 5.11. Bladder Cancer
    • 5.11.1. Key Market Trends, Growth Factors and Opportunities
    • 5.11.2. Market Size and Forecast, By Region
    • 5.11.3. Market Share Analysis, By Country
  • 5.12. Other Cancers
    • 5.12.1. Key Market Trends, Growth Factors and Opportunities
    • 5.12.2. Market Size and Forecast, By Region
    • 5.12.3. Market Share Analysis, By Country

CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Drug Class
    • 6.2.3. Market Size and Forecast, By Indication
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Oncology-Cancer Drugs Market
      • 6.2.5.1. Market Size and Forecast, By Drug Class
      • 6.2.5.2. Market Size and Forecast, By Indication
    • 6.2.6. Canada Oncology-Cancer Drugs Market
      • 6.2.6.1. Market Size and Forecast, By Drug Class
      • 6.2.6.2. Market Size and Forecast, By Indication
    • 6.2.7. Mexico Oncology-Cancer Drugs Market
      • 6.2.7.1. Market Size and Forecast, By Drug Class
      • 6.2.7.2. Market Size and Forecast, By Indication
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Drug Class
    • 6.3.3. Market Size and Forecast, By Indication
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Oncology-Cancer Drugs Market
      • 6.3.5.1. Market Size and Forecast, By Drug Class
      • 6.3.5.2. Market Size and Forecast, By Indication
    • 6.3.6. France Oncology-Cancer Drugs Market
      • 6.3.6.1. Market Size and Forecast, By Drug Class
      • 6.3.6.2. Market Size and Forecast, By Indication
    • 6.3.7. UK Oncology-Cancer Drugs Market
      • 6.3.7.1. Market Size and Forecast, By Drug Class
      • 6.3.7.2. Market Size and Forecast, By Indication
    • 6.3.8. Italy Oncology-Cancer Drugs Market
      • 6.3.8.1. Market Size and Forecast, By Drug Class
      • 6.3.8.2. Market Size and Forecast, By Indication
    • 6.3.9. Spain Oncology-Cancer Drugs Market
      • 6.3.9.1. Market Size and Forecast, By Drug Class
      • 6.3.9.2. Market Size and Forecast, By Indication
    • 6.3.10. Rest of Europe Oncology-Cancer Drugs Market
      • 6.3.10.1. Market Size and Forecast, By Drug Class
      • 6.3.10.2. Market Size and Forecast, By Indication
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Drug Class
    • 6.4.3. Market Size and Forecast, By Indication
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Oncology-Cancer Drugs Market
      • 6.4.5.1. Market Size and Forecast, By Drug Class
      • 6.4.5.2. Market Size and Forecast, By Indication
    • 6.4.6. Japan Oncology-Cancer Drugs Market
      • 6.4.6.1. Market Size and Forecast, By Drug Class
      • 6.4.6.2. Market Size and Forecast, By Indication
    • 6.4.7. India Oncology-Cancer Drugs Market
      • 6.4.7.1. Market Size and Forecast, By Drug Class
      • 6.4.7.2. Market Size and Forecast, By Indication
    • 6.4.8. Australia Oncology-Cancer Drugs Market
      • 6.4.8.1. Market Size and Forecast, By Drug Class
      • 6.4.8.2. Market Size and Forecast, By Indication
    • 6.4.9. South Korea Oncology-Cancer Drugs Market
      • 6.4.9.1. Market Size and Forecast, By Drug Class
      • 6.4.9.2. Market Size and Forecast, By Indication
    • 6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
      • 6.4.10.1. Market Size and Forecast, By Drug Class
      • 6.4.10.2. Market Size and Forecast, By Indication
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Drug Class
    • 6.5.3. Market Size and Forecast, By Indication
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Oncology-Cancer Drugs Market
      • 6.5.5.1. Market Size and Forecast, By Drug Class
      • 6.5.5.2. Market Size and Forecast, By Indication
    • 6.5.6. South Africa Oncology-Cancer Drugs Market
      • 6.5.6.1. Market Size and Forecast, By Drug Class
      • 6.5.6.2. Market Size and Forecast, By Indication
    • 6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
      • 6.5.7.1. Market Size and Forecast, By Drug Class
      • 6.5.7.2. Market Size and Forecast, By Indication
    • 6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
      • 6.5.8.1. Market Size and Forecast, By Drug Class
      • 6.5.8.2. Market Size and Forecast, By Indication

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. AbbVie Inc.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Amgen
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Astellas Pharma Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. AstraZeneca Plc
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Bristol-Myers Squibb Company
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. F. Hoffmann-La Roche Ltd.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Johnson And Johnson
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Merck And Co., Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Novartis AG
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Pfizer Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments